MVMiriam Valentini

Miriam Valentini

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Miriam Valentini has a total of 223 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 9 July 2013
      • Vol. 30  (2)

    [Effects of dose of erythropoiesis stimulating agents on cardiovascular outcomes, quality of life and costs of haemodialysis. the clinical evaluation of the DOSe of erythropoietins (C.E. DOSE) Trial].

    by V Saglimbene, D D'Alonzo, M Ruospo, M Vecchio, P Natale, L Gargano, A Nicolucci, F Pellegrini, J C Craig, G Triolo, et al.

    Anaemia is a risk factor for death, adverse cardiovascular outcomes and poor quality of life in patients with chronic kidney disease (CKD). Erythropoietin Stimulating Agents (ESA) are the most used treatment option. In observational studies, higher haemoglobin (Hb) levels (around 11-13 g/dL) are associated with improved survival and quality of life compared to Hb levels around 9-10 g/dL. Randomized studies found that targeting higher Hb levels with ESA causes an increased risk of death, mainly due to adverse cardiovascular outcomes. It is possible that this is mediated by ESA dose rather than haemoglobin concentration, although this hypothesis has never been formally tested. We present the protocol of the Clinical Evaluation of the Dose of Erythropoietins (C.E. DOSE) trial, which will assess the benefits and harms of a high versus a low ESA dose therapeutic strategy for the management of anaemia of end stage kidney disease (ESKD). This is a randomized, prospective open label blinded end-point (PROBE) design trial due to enroll 900 haemodialysis patients. Patients will be randomized 1:1 to 4000 UI/week i. v. versus 18000 UI/week i. v. of epoetin alfa, beta or any other epoetin in equivalent doses. The primary outcome of the trial is a composite of cardiovascular events. In addition, quality of life and costs of these two strategies will be assessed. The study has been approved and funded by the Italian Agency of Drugs (Agenzia Italiana del Farmaco (AIFA)) within the 2006 funding plan for independent research on drugs (registered at www.clinicaltrials.gov (NCT00827021)).


  • Top Cited Papers
    Open Access

    Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

    by Christina Davies, Hongchao Pan, Jon Godwin, Richard Gray, Rodrigo Arriagada, Vinod Raina, Mirta Abraham, Victor Hugo Medeiros Alencar, Atef Badran, Xavier Bonfill, et al.


  • Andamento e stato della ricerca sul cancro della mammella: una analisi della letteratura

    by Miriam Valentini, Alessia Milesi

    Le neoplasie mammarie sono quelle più frequenti nel sesso femminile. Un valido aiuto per la loro gestione potrebbe venire dall’Outcomes Research, cioè da quella ricerca che mira a comprendere i risultati finali di particolari processi di cura e di intervento. Una recente revisione della letteratura aiuta a capire quale sia l’interesse per questo tipo di ricerca e quali potrebbero essere gli sviluppi futuri.

  • Open Access

    Type and trends in outcomes research in breast cancer between 2000 and 2007

    by M. Valentini, A. Milesi, A. Bettini, C. Tondini, A. Nicolucci

    Background: Interest in outcomes research (OR) derives from the need to know the value and the effectiveness of health interventions, especially for oncology. We focused our research on OR in breast cancer, providing an overview of the trend of publications. Patients and methods: We carried out a Medline search to retrieve all articles in English published from 2000 through 2007. The abstracts were reviewed and classified according to the research topics and the primary design of the trial. Results: We selected 405 articles: their number remained constant until 2003, rose during 2004–2005 and decreased during the last 2 years. The most common topic was surgery (n = 234), alone or in association with other interventions. The category more investigated was the process. Clinical outcomes, and among them disease-free survival, were more frequent than other outcomes. The median value of 2007 Impact Factor of the journals publishing the selected references was 2.466 (range 0.272–25.547) and the median value of Citation Index was 8 (range 0–143). Conclusions: Our research showed a decreasing interest in OR during the more recent years. We are hopeful that it will regenerate interest, particularly by the light of the funds allocated to the comparative effectiveness research in the United States.


  • How to conduct a randomized trial

    by Alicia Smith, Suetonia Palmer, David W Johnson, Sankar Navaneethan, Miriam Valentini, Giovanni Fm Strippoli

    Randomized controlled clinical trials represent the gold standard of research into health-care interventions but conducting a randomized trial requires careful planning, structures and procedures. The conduct of a clinical trial is a collaborative effort between investigators, participants and a range of professionals involved both centrally and locally in the coordination and execution of the study. In this article, the key steps to conducting a randomized controlled trial are summarized.


    • 3 June 2010
      • Vol. 29  (1) , 26-40

    [Memorandum for the management of clinical trials].

    by Miriam Valentini, Maria Celeste Pirozzoli, Daniela D'alonzo, Luisella Pirozzi, Caterina Anecchino, Francesca Tuzi, Marilena Romero, Antonio Nicolucci, Giovanni F M Strippoli, Maurizio Belfiglio, et al.

    A critical appraisal of the recent legislation on clinical trials is proposed, together with some reflections on the implications on the practice and principles of clinical experimentation. The possible role and contribution of Ethical Committees is discussed.

  • Open Access

    Long-term Effectiveness of Adjuvant Goserelin in Premenopausal Women With Early Breast Cancer

    by Allan Hackshaw, Michael Baum, Tommy Fornander, B. Nordenskjold, Antonio Nicolucci, Kathryn Monson, Sharon Forsyth, Krystyna Reczko, Ulla Johansson, Helena Fohlin, et al.

    Systematic reviews have found that luteinizing hormone–releasing hormone (LHRH) agonists are effective in treating premenopausal women with early breast cancer. We conducted long-term follow-up (median 12 years) of 2706 women in the Zoladex In Premenopausal Patients (ZIPP), which evaluated the LHRH agonist goserelin (3.6 mg injection every 4 weeks) and tamoxifen (20 or 40 mg daily), given for 2 years. Women were randomly assigned to receive each therapy alone, both, or neither, after primary therapy (surgery with or without radiotherapy/chemotherapy). Hazard ratios and absolute risk differences were used to assess the effect of goserelin treatment on event-free survival (breast cancer recurrence, new tumor or death), overall survival, risk of recurrence of breast cancer, and risk of dying from breast cancer, in the presence or absence of tamoxifen. Fifteen years after the initiation of treatment, for every 100 women not given tamoxifen, there were 13.9 (95% confidence interval [CI] = 17.5 to 19.4) fewer events among those who were treated with goserelin compared with those who were not treated with goserelin. However, among women who did take tamoxifen, there were 2.8 fewer events (95% CI = 7.7 fewer to 2.0 more) per 100 women treated with goserelin compared with those not treated with goserelin. The risk of dying from breast cancer was also reduced at 15 years: For every 100 women given goserelin, the number of breast cancer deaths was lower by 2.6 (95% CI = 6.6 fewer to 2.1 more) and 8.5 (95% CI = 2.2 to 13.7) in those who did and did not take tamoxifen, respectively, although in the former group the difference was not statistically significant. Two years of goserelin treatment was as effective as 2 years of tamoxifen treatment 15 years after starting therapy. In women who did not take tamoxifen, there was a large benefit of goserelin treatment on survival and recurrence, and in women who did take tamoxifen, there was a marginal potential benefit on these outcomes when goserelin was added.


  • Quality of diabetes care predicts the development of cardiovascular events: Results of the QuED study

    by Giorgia De Berardis, Fabio Pellegrini, Monica Franciosi, Maurizio Belfiglio, Barbara Di Nardo, Sheldon Greenfield, Sherrie H. Kaplan, Maria C.E. Rossi, Michele Sacco, Gianni Tognoni, et al.


  • Open Access

    Identifying Patients at Risk for Microalbuminuria via Interaction of the Components of the Metabolic Syndrome

    by Monica Franciosi, Fabio Pellegrini, Michele Sacco, Giorgia De Berardis, Maria C.E. Rossi, Giovanni F.M. Strippoli, Maurizio Belfiglio, Gianni Tognoni, Miriam Valentini, Antonio Nicolucci

    Background and objectives: The objective of this study was to investigate correlates of risk for having microalbuminuria in individuals with one or more cardiovascular risk factors.


  • Clinical and Psychological Predictors of Incidence of Self-Reported Erectile Dysfunction in Patients With Type 2 Diabetes

    by Giorgia De Berardis, Fabio Pellegrini, Monica Franciosi, Maurizio Belfiglio, Barbara Di Nardo, Sheldon Greenfield, Sherrie H. Kaplan, Maria C.E. Rossi, Michele Sacco, Gianni Tognoni, et al.

    We evaluated the predictors of the incidence of erectile dysfunction in patients with type 2 diabetes mellitus and identified subgroups of patients in whom the interaction between clinical and psychological characteristics determined an increase in the risk of erectile dysfunction. The study was based on 670 individuals. The presence of erectile dysfunction and the severity of depressive symptoms were investigated with a questionnaire filled in every 6 months for 3 years. Poisson regression was used to calculate incidence rates. To evaluate interactions among the different variables and identify distinct and homogeneous subgroups in terms of incidence of erectile dysfunction, RECursive Partitioning and AMalgamation method was used. Overall erectile dysfunction developed in 192 men with type 2 diabetes, with an incidence rate of 166.3 per 1,000 person-years. Age, insulin treatment, hemoglobin A1c greater than 8.0%, total cholesterol greater than 3.88 mmol/l and severity of depressive symptoms represented independent predictors of erectile dysfunction. RECursive Partitioning and AMalgamation analysis identified 5 classes with a marked variation in the risk of erectile dysfunction. Patients with low levels of depressive symptoms and hemoglobin A1c 8.0% or less showed the lowest risk of erectile dysfunction. Compared with this subgroup patients with higher levels of depressive symptoms and treated with insulin had a 3-fold risk of erectile dysfunction. Age, smoking, high cholesterol levels and neuropathy were globally predictive variables associated with an increased risk of erectile dysfunction. The incidence of erectile dysfunction is predicted by modifiable risk factors. Even in diabetes, psychological problems can contribute to the pathogenesis of erectile dysfunction, in addition to organic causes.